Since in some tumors, such as melanoma, BRAF and MEK inhibitors are frequently used and resistance mechanisms develop several months after their use, the identification of inhibitors that allow the possibility to block alternative targets of the tumor, regulating cell cycle and apoptosis, may represent an important goal and can be considered for the design of new combinatorial therapies based to the inhibition of multiple targets at the same time [67]. This evidence concerns the gene BRAF and melanoma.